


Collaborative Research

Interdisciplinary centers
in one of the world's most active and
concentrated bioscience hubs, the
Torrey Pines Mesa



4

**Disease-Focused
Centers**

2

**Enabling Technology
Centers**

Innovative Science

Top 2% of research institutions
worldwide based on citations per paper

169 peer-reviewed papers
published in 2024

Top 9% in the nation: Nature Index
of nonprofit/non-government
institutions in biomedical science

1,444 patents
from Sanford Burnham Prebys
innovations



4 out of 5

people are directly
connected to research

**SCIENTISTS AND
ADMINISTRATORS..... 575**

Outstanding Education

Our WSCUC-accredited graduate
school is recognized for customized
curriculum and accelerated
time-to-degree

74 graduates to date

89% retention rate

Time-to-degree **<5 years**

Trainees pursue a wide range of
careers in biotech, academia and
research

Accolades and Achievements

3 members of the National
Academies of Sciences, Engineering
and Medicine

3 Highly Cited Researchers
(top 1% by citations for their field)

1 Lasker Award winner
often referred to as "America's Nobel"

Since 1981, 1 of 7
NCI-designated basic cancer
research centers in the nation

13 new faculty recruits
since 2023

We Translate Science Into Health

We are in the midst of a biomedical
revolution, one in which the old ways
of thinking about and doing science
no longer adequately address the
complexities of modern research or
the greater needs in public health.

Sanford Burnham Prebys is changing
this reality by combining distinct and
powerful resources with collaborative,
interdisciplinary research focused on
the most critical diseases. We are
forward-thinking: Training current and
new generations of scientists and
innovators with the most advanced
technologies.

Annual Budget

FY 2026

TOP 3
of all independent research
institutes ranked by NIH funding

| | |
|-----------------------------|-----|
| FEDERAL GRANTS | 68% |
| PHILANTHROPY..... | 11% |
| LICENSING & OTHER..... | 10% |
| OTHER GRANTS..... | 4% |
| STATE SUPPORT..... | 4% |
| BIOPHARMA PARTNERSHIPS..... | 3% |

\$105M
Annual Revenue

Science

In The Service Of Health

Our goal is to transform basic research into new drugs and treatments as quickly as possible. That means getting innovative ideas into clinical trials and ultimately, to doctors and their patients.



supported by Sanford Burnham Prebys research

SELECT CURRENT CLINICAL TRIALS

Ongoing trials supported by Sanford Burnham Prebys research

Tobacco use disorder

A drug discovered in the lab of Nicholas Cosford, PhD, professor and deputy director of our NCI-designated Cancer Center, has successfully completed a Phase I clinical study. The compound, SBP-9330, targets a neuronal pathway underlying addictive behaviors and would be a first-in-class oral therapeutic to help people quit smoking.

Ectopic calcification diseases

Foundational research has led to Phase II clinical trial to assess a compound that inhibits calcium deposits in parts of the body where they shouldn't be. The compound, DS-1211, is being tested on individuals with pseudoxanthoma elasticum, a progressive genetic disorder that primarily affects skin, eyes and blood vessels, but may have broader applications.

Pancreatic cancer

A compound discovered by Erkki Ruoslahti, PhD, and colleagues is being evaluated in multiple Phase II trials for cancer, including pancreatic cancer and other solid tumors. The compound, LSTA-1, is used with existing cancer drugs to boost penetration into solid tumors. Ruoslahti also developed the CendR technology used in trial, which delivers anti-cancer drugs deeper into targeted solid tumors.

TREATMENTS AND TESTS IN THE CLINIC

FDA-approved treatments and tests supported by Sanford Burnham Prebys research

Venclexta™ (2016)

Chronic lymphocytic leukemia (CLL)

Venclexta™ is used to treat people with chronic CLL or small lymphocytic lymphoma (SLL), who have received at least one prior treatment. Sanford Burnham Prebys scientists performed fundamental cancer research that led to the identification of the drug.

Strensiq® (2015)

Hypophosphatasia or soft bone disease

Strensiq® is an innovative enzyme replacement therapy for the treatment of patients with perinatal/infantile and juvenile-onset hypophosphatasia (HPP), a genetic, chronic, progressive and life-threatening metabolic disease with debilitating or life-threatening complications. Sanford Burnham Prebys scientists performed key studies on the normal skeletal and mineralization mechanisms.

Aggrastat® (2000)

Preventing blood clots

Aggrastat is a type of "blood thinner" prescribed for people at risk of a heart attack or other serious blood flow problems. Sanford Burnham Prebys scientists performed fundamental research on the biology of blood clotting.

Targretin® (1999)

Cutaneous t-cell lymphoma

Targretin® is used to treat skin problems from cutaneous T-cell lymphoma in patients who have not responded well to other treatments. Sanford Burnham Prebys scientists performed research that helped identify the drug.

Integrilin® (1998)

Preventing blood clots during a heart attack or angioplasty

Every 40 seconds, someone in the U.S. has a heart attack caused by a blood clot. Angioplasty is a procedure that opens blocked arteries and restores normal blood flow to the heart muscle. Sanford Burnham Prebys contributed to the research that enabled the development of Integrilin.

PSA Test (1994)

Screening for prostate cancer

The PSA test is the most common screening tool for prostate cancer. It measures blood levels of a protein called prostate-specific antigen. Elevated levels may indicate prostate cancer. Before coming to Sanford Burnham Prebys, scientist Eva Engvall, MD, PhD, co-invented the original testing method, called the ELISA test, which has also been used to detect the viruses that cause HIV and COVID-19.

Epogen® (1989 and 1993)

Anemia caused by chronic renal disease and chemotherapy

Nearly 500,000 Americans require dialysis treatment for chronic kidney disease. Nearly all experience anemia. They are given Epogen®, which reduces the need for blood transfusions. Sanford Burnham Prebys scientists created the technology that enabled development of Epogen®.

Developing Prototype Drugs

One of the most advanced nonprofit drug discovery centers

Industry-trained personnel have a track record of discovering and developing novel therapeutics

60+ drug discovery projects, many with advanced chemical leads, including neuroscience, oncology, metabolic and cardiovascular disease and immunology/infectious disease

\$100M+ of translational science grants in the last 5 years

Our Mission

Energize, accelerate and reimagine translational research to create and deliver new therapies, faster and better, that improve human lives, health and well-being.